GeneCradle / 锦篮基因

The company's mission is to translate gene therapy research from the laboratory to clinical applications and the market, making treatments accessible to patients with rare diseases in China and globally. GeneCradle focuses on developing treatments for hereditary conditions, including neuromuscular diseases, genetic metabolic diseases, lysosomal storage disorders, and ophthalmic diseases. Its business model involves the entire drug development pipeline, from research and development and preclinical evaluation to GMP-compliant manufacturing and clinical trials. The company's drug development pipeline includes several platforms, such as a Carrier Shell Engineering Modification Platform (RuiCAP) and a Gene Element Design Optimization Platform (RuiELEMENT).

Since its founding, GeneCradle has reached several milestones. In 2003, the founding team successfully applied for China's first clinical trial of an AAV gene drug for hemophilia B. The company has secured significant funding over several rounds, raising a total of $31.4M from investors including Oriental Fortune Capital, Qiandao Fund, and Shenzhen Capital Group. Notable clinical advancements include the successful launch of a Phase III trial for its GC101 drug for Spinal Muscular Atrophy (SMA) and the publication of clinical research for its GC301 gene therapy for Pompe Disease. Keywords: gene therapy, AAV vectors, rare diseases, drug development, biopharmaceutical, neuromuscular diseases, genetic metabolic diseases, clinical trials, lysosomal diseases, ophthalmology